Neoadjuvant mFOLFOX6 plus camrelizumab and apatinib in colon cancer and biomarker research via spatiotemporal-omics profiling.

NPJ Precis Oncol · 2026 · PMC13212963 · PMID 41922688

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

A decreasing trend in resMAC-enriched CN11 was observed in the pCR group compared with the nonpCR group, although the difference was not statistically significant (Fig. 5E ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.